Free tool
FAERS Monitor: R-Gene 10
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 016931 or its brand name (R-Gene 10, Arginine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
103
Serious
83
81% of reports
Hospitalization
41
Death reported
8
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hypotension10
- off label use8
- haematuria7
- vomiting7
- diarrhoea6
- nausea6
- cardiac disorder5
- drug ineffective5
- fatigue5
- malaise5
- atrial fibrillation4
- cough4
- pyrexia4
- renal impairment4
- acidosis hyperchloraemic3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 1 |
| 2010 | 10 |
| 2011 | 3 |
| 2012 | 6 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 4 |
| 2016 | 7 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 7 |
| 2020 | 3 |
| 2021 | 8 |
| 2022 | 8 |
| 2023 | 9 |
| 2024 | 7 |
| 2025 | 13 |
| 2026 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,056 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acidosis hyperchloraemicSignal | 3 | 1037.6 | 339.3 | 2,146 |
| haematuriaSignal | 7 | 41.8 | 20.4 | 240 |
| cardiac disorderSignal | 5 | 10.9 | 4.6 | 36 |
| hypotensionSignal | 10 | 10.2 | 5.6 | 75 |
| renal impairmentSignal | 4 | 9.7 | 3.7 | 23 |
| atrial fibrillationSignal | 4 | 8.4 | 3.2 | 19 |
| vomitingSignal | 7 | 3.0 | 1.5 | 8 |
| cough | 4 | 2.9 | 1.1 | 3 |
| pyrexia | 4 | 2.4 | 0.9 | 2 |
| malaise | 5 | 2.3 | 1.0 | 3 |
| diarrhoea | 6 | 1.9 | 0.9 | 2 |
| off label use | 8 | 1.9 | 1.0 | 3 |
| nausea | 6 | 1.5 | 0.7 | 1 |
| fatigue | 5 | 1.3 | 0.6 | 0 |
| drug ineffective | 5 | 0.8 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.